Literature DB >> 25316845

Poliomyelitis eradication in China: 1953-2012.

Wen-Zhou Yu1, Ning Wen1, Yong Zhang2, Hai-Bo Wang1, Chun-Xiang Fan1, Shuang-Li Zhu2, Wen-Bo Xu2, Xiao-Feng Liang1, Hui-Ming Luo1, Li Li1.   

Abstract

BACKGROUND: Poliomyelitis has historically been endemic in China and has been considered an important cause of disability and death.
METHODS: We reviewed strategies and measures of poliomyelitis control and eradication from 1953 to 2012. Data from notifiable disease and routine immunization reporting systems and acute flaccid paralysis (AFP) surveillance were analyzed.
RESULTS: About 20 000 poliomyelitis cases were reported annually in the prevaccine era. During 1965-1977, live, attenuated oral poliomyelitis vaccine (OPV) was administered to children through annual mass campaigns in the winter, and the number of poliomyelitis cases started to decline. A cold chain system was established during 1982, and OPV coverage increased during the early stage of the Expanded Programme on Immunization, from 1978 to 1988. Between 1989 and 1999, routine immunization was strengthened, supplementary immunization activities (SIAs) were conducted, and the AFP surveillance system was established. China reported a last indigenous poliomyelitis case in 1994 and was certified as free of polio in 2000. To maintain its polio-free status, China kept >90% coverage of 3 doses of OPV, conducted SIAs in high-risk areas, and maintained high-quality of AFP surveillance. China succeeded in stopping the outbreak in Xinjiang in 2011.
CONCLUSIONS: China's polio-free status was achieved and maintained through strengthening routine immunization and implementing SIAs and AFP surveillance.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  China; eradication; poliomyelitis

Mesh:

Substances:

Year:  2014        PMID: 25316845     DOI: 10.1093/infdis/jit332

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Seroprevalence of poliovirus antibodies before and after polio vaccine switch in 2012 and 2017 in Beijing.

Authors:  Juan Li; Zhujiazi Zhang; Herun Zhang; Maozhong Li; Xiaomei Li; Li Lu; Fang Huang; Jiang Wu
Journal:  Hum Vaccin Immunother       Date:  2020-07-23       Impact factor: 3.452

2.  Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019-2023.

Authors:  Peng Chen; Yao Liu; Haiyan Wang; Guifang Liu; Xiaojuan Lin; Weiyan Zhang; Feng Ji; Qing Xu; Zexin Tao; Aiqiang Xu
Journal:  Appl Environ Microbiol       Date:  2020-07-20       Impact factor: 4.792

3.  An outbreak following importation of wild poliovirus in Xinjiang Uyghur Autonomous Region, China, 2011.

Authors:  Hai-Bo Wang; Wen-Zhou Yu; Xin-Qi Wang; Fuerhati Wushouer; Jian-Ping Wang; Dong-Yan Wang; Fu-Qiang Cui; Jing-Shan Zheng; Ning Wen; Yi-Xin Ji; Chun-Xiang Fan; Hui-Ling Wang; Gui-Jun Ning; Guo-Hong Huang; Dong-Mei Yan; Qi-Ru Su; Da-Wei Liu; Guo-Min Zhang; Kathleen H Reilly; Jing Ning; Jian-Ping Fu; Sha-Sha Mi; Hui-Ming Luo; Wei-Zhong Yang
Journal:  BMC Infect Dis       Date:  2015-01-31       Impact factor: 3.090

4.  Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants.

Authors:  Ting Zhao; Zhaojun Mo; Zhifang Ying; Teng Huang; Yanchun Che; Guoliang Li; Xiaolei Yang; Mingbo Sun; Li Jiang; Li Shi; Hui Ye; Zhimei Zhao; Xiaochang Liu; Jing Li; Yanping Li; Rongcheng Li; Ruiju Jiang; Jianfeng Wang; Yuting Fu; Rufei Ma; Hongyuan Shi; Huan Yang; Changgui Li; Jingsi Yang; Qihan Li
Journal:  Ann Transl Med       Date:  2021-02

5.  Non-neutralizing Antibody Responses against VP1 in Enterovirus A, B, C and Rhinovirus A species among Infants and Children in Shanghai.

Authors:  Yingying Ding; Bing Rui; Caixia Gao; Menghua Xu; Lili Wang; Chunyan Zhao; Jie Bai; Jinhong Wang; Jin Xu; Wei Pan
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

6.  The landscape of vaccines in China: history, classification, supply, and price.

Authors:  Yaming Zheng; Lance Rodewald; Juan Yang; Ying Qin; Mingfan Pang; Luzhao Feng; Hongjie Yu
Journal:  BMC Infect Dis       Date:  2018-10-04       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.